UBS reports that hedge funds are beginning to reduce their exposure to artificial intelligence (AI) stocks, which have become the most crowded segment in equity markets. While investors still believe in the long-term potential of AI, confidence is waning due to risks associated with many funds holding the same positions. UBS highlights concerns that AI spending growth may hit a "speed limit," potentially leaving supply chains short of upgrades and crowded trades vulnerable. Hedge funds are shifting focus towards other sectors like US industrials, financials, and healthcare as they seek new opportunities amid accelerating US economic growth. European shares see limited interest from US investors, though banks remain favored for their dividends and profitability despite economic headwinds in Europe.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
CHARBONE Corporation has increased its helium delivery fleet from one to five units to meet rising demand caused by global helium supply disruptions, notably from Qatar. This expansion supports North American customers in sectors like semiconductors ...
Citi has started coverage of Hikma Pharmaceuticals with a 'buy' rating and a £17 price target, highlighting the company's strategic shift towards differentiated products and US manufacturing investments. The broker sees a 14% potential share price re...
Xenon Pharmaceuticals is evolving into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform. Its lead drug candidate, azetukalner, has shown strong effectiveness in treating refractory focal onset seizures and ...
